Drug Innovation Drive Growth At Cipher Pharmaceuticals

Cipher Pharmaceuticals is transitioning from a royalty-based model to a direct dermatology business, focusing on innovative products like a tattoo removal cream and Sitavig for cold sores. The company aims to penetrate the US and Canadian markets, leveraging its strategic acquisitions and product pipeline. Despite a net quarterly loss, Cipher is investing in growth, particularly in dermatology, a commercially attractive sector. The company plans to become a leading dermatology firm by 2020, driven by innovation and market demand.

How does the cold sore medication developed by Cipher Pharmaceuticals differ from existing treatments?

What is the significance of the dermatology market's size and growth potential for Cipher Pharmaceuticals?

What are Cipher Pharmaceuticals' goals for the future in the dermatology sector?